KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Tax Provisions (2016 - 2025)

Nektar Therapeutics has reported Tax Provisions over the past 16 years, most recently at $31000.0 for Q4 2025.

  • Quarterly results put Tax Provisions at $31000.0 for Q4 2025, up 111.97% from a year ago — trailing twelve months through Dec 2025 was -$138000.0 (up 42.26% YoY), and the annual figure for FY2025 was -$138000.0, up 42.26%.
  • Tax Provisions for Q4 2025 was $31000.0 at Nektar Therapeutics, up from -$33000.0 in the prior quarter.
  • Over the last five years, Tax Provisions for NKTR hit a ceiling of $436000.0 in Q4 2022 and a floor of -$259000.0 in Q4 2024.
  • Median Tax Provisions over the past 5 years was $38500.0 (2024), compared with a mean of $36450.0.
  • Biggest five-year swings in Tax Provisions: surged 433.33% in 2021 and later crashed 508.7% in 2025.
  • Nektar Therapeutics' Tax Provisions stood at $98000.0 in 2021, then soared by 344.9% to $436000.0 in 2022, then crashed by 74.54% to $111000.0 in 2023, then tumbled by 333.33% to -$259000.0 in 2024, then soared by 111.97% to $31000.0 in 2025.
  • The last three reported values for Tax Provisions were $31000.0 (Q4 2025), -$33000.0 (Q3 2025), and -$188000.0 (Q2 2025) per Business Quant data.